Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0J6AB
|
|||
| Former ID |
DCL000572
|
|||
| Drug Name |
MK-5108
|
|||
| Synonyms |
1010085-13-8; VX-689; MK 5108; MK5108; MK-5108 (VX-689); UNII-H8J407531S; VX689; VX 689; CHEMBL3600873; H8J407531S; 4-(3-chloro-2-fluorophenoxy)-1-[[6-(1,3-thiazol-2-ylamino)pyridin-2-yl]methyl]cyclohexane-1-carboxylic acid; 4-(3-Chloranyl-2-Fluoranyl-Phenoxy)-1-[[6-(1,3-Thiazol-2-Ylamino)pyridin-2-Yl]methyl]cyclohexane-1-Carboxylic Acid; (1r,4r)-4-(3-chloro-2-fluorophenoxy)-1-((6-(thiazol-2-ylamino)pyridin-2-yl)methyl)cyclohexane-1-carboxylic acid; Cyclohexanecarboxylic acid,; MK-5108/VX-689
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H21ClFN3O3S
|
|||
| Canonical SMILES |
C1CC(CCC1OC2=C(C(=CC=C2)Cl)F)(CC3=NC(=CC=C3)NC4=NC=CS4)C(=O)O
|
|||
| InChI |
1S/C22H21ClFN3O3S/c23-16-4-2-5-17(19(16)24)30-15-7-9-22(10-8-15,20(28)29)13-14-3-1-6-18(26-14)27-21-25-11-12-31-21/h1-6,11-12,15H,7-10,13H2,(H,28,29)(H,25,26,27)
|
|||
| InChIKey |
LCVIRAZGMYMNNT-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1010085-13-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
49650216, 50082338, 136345851, 136367506, 136946400, 140461525, 141492910, 144116230, 152159565, 152258490, 160647325, 162011959, 164193996, 172650685, 174006374, 177749657, 186014854, 186526079, 189561491, 198943204, 223389038, 223705109, 227705685, 227705688, 242060386, 242585457, 246152918, 246268388, 249565741, 251963164, 252160606, 252215822, 252451773, 252552935
|
|||
| ChEBI ID |
CHEBI:125340
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Aurora kinase A (AURKA) | Target Info | Inhibitor | [3], [4] |
| Aurora kinase B (AURKB) | Target Info | Inhibitor | [3], [4] | |
| KEGG Pathway | Oocyte meiosis | |||
| Pathway Interaction Database | Aurora B signaling | |||
| Signaling by Aurora kinases | ||||
| Aurora C signaling | ||||
| FOXM1 transcription factor network | ||||
| Aurora A signaling | ||||
| Integrin-linked kinase signaling | ||||
| PLK1 signaling events | ||||
| Reactome | APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | |||
| Separation of Sister Chromatids | ||||
| Resolution of Sister Chromatid Cohesion | ||||
| RHO GTPases Activate Formins | ||||
| Mitotic Prometaphase | ||||
| Regulation of PLK1 Activity at G2/M Transition | ||||
| WikiPathways | Mitotic Metaphase and Anaphase | |||
| Mitotic Prometaphase | ||||
| Regulation of Microtubule Cytoskeleton | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| APC/C-mediated degradation of cell cycle proteins | ||||
| EGF/EGFR Signaling Pathway | ||||
| JAK/STAT | ||||
| Gastric Cancer Network 1 | ||||
| Integrated Breast Cancer Pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8061). | |||
| REF 2 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026594) | |||
| REF 3 | A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8. | |||
| REF 4 | Anticancer activity of the Aurora A kinase inhibitor MK-5108 in non-small-cell lung cancer (NSCLC) in vitro as monotherapy and in combination with chemotherapies. J Cancer Res Clin Oncol. 2014 Jul;140(7):1137-49. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.